Ceritinib Patent Expiration
Ceritinib is Used for treating cancers mediated by anaplastic lymphoma kinase (ALK). It was first introduced by Novartis Pharmaceuticals Corp
Ceritinib Patents
Given below is the list of patents protecting Ceritinib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Zykadia | US8703787 | Methods of using ALK inhibitors | Feb 02, 2032 | Novartis |
| Zykadia | US9309229 | Crystalline forms of 5-chloro-N2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine | Jan 18, 2032 | Novartis |
| Zykadia | US8039474 | 2,3,4,9-tetrahydro-1H-carbazole derivatives as CRTH2 receptor antagonists | Jun 29, 2030 | Novartis |
| Zykadia | US8039479 | Compounds and compositions as protein kinase inhibitors | Jun 29, 2030 | Novartis |
| Zykadia | US7964592 | 2,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders | Apr 29, 2028 | Novartis |
| Zykadia | US8377921 | Compounds and compositions as protein kinase inhibitors | Nov 20, 2027 | Novartis |
| Zykadia | US8399450 | Compounds and compositions as protein kinase inhibitors | Nov 20, 2027 | Novartis |
| Zykadia | US7893074 | 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders | Apr 25, 2026 | Novartis |
| Zykadia | US8188276 | 2,4-pyrimidinediamine compounds and their uses |
Jan 31, 2023
(Expired) | Novartis |
| Zykadia | US8835430 | 2,4-pyrimidinediamine compounds and their uses |
Jan 31, 2023
(Expired) | Novartis |
| Zykadia | US9018204 | 2,4-pyrimidinediamine compounds and their uses |
Jan 31, 2023
(Expired) | Novartis |
| Zykadia | US9416112 | 2,4-pyrimidinediamine compounds and their uses |
Jan 31, 2023
(Expired) | Novartis |
| Zykadia | US7153964 | Pyrimidine compounds |
Feb 26, 2021
(Expired) | Novartis |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Ceritinib's patents.
Latest Legal Activities on Ceritinib's Patents
Given below is the list recent legal activities going on the following patents of Ceritinib.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 01 Jul, 2024 | US8188276(Litigated) |
| Maintenance Fee Reminder Mailed Critical | 08 Apr, 2024 | US9416112 |
| Change in Power of Attorney (May Include Associate POA) Critical | 15 Feb, 2024 | US8188276(Litigated) |
| Email Notification Critical | 15 Feb, 2024 | US8188276(Litigated) |
| Email Notification Critical | 14 Feb, 2024 | US9416112 |
| Change in Power of Attorney (May Include Associate POA) Critical | 14 Feb, 2024 | US9416112 |
| Email Notification Critical | 13 Feb, 2024 | US8835430(Litigated) |
| Change in Power of Attorney (May Include Associate POA) Critical | 13 Feb, 2024 | US8835430(Litigated) |
| Maintenance Fee Reminder Mailed Critical | 15 Jan, 2024 | US8188276(Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 27 Sep, 2023 | US9309229 |
Ceritinib's Family Patents
